University of Maryland School of Medicine Baltimore, Maryland
In this session, we will review the evidence base for use of anti-integrins and S1P modulators in the treatment of patients with IBD. The session will review the data on effectiveness of these agents in the pivotal clinical trials leading to their approval as well as long term safety data for both classes of drugs. The review of safety will include data across disease states if available. At the conclusion of this session, we will discuss how providers should position these agents in clinical practice for the care of patients with CD (vedolizumab only) and UC (vedolizumab and ozanimod).
Learning Objectives:
Review the evidence base for use of anti-integrins in the treatment of patients with IBD
Review the evidence base for use of S1P modulators in the treatment of patients with ulcerative colitis
Discuss positioning of anti-integrins and S1P modulators in clinical IBD practice